Procrit Sales Slump Continues Due To 10% Year-Over-Year Price Decline
This article was originally published in The Pink Sheet Daily
Executive Summary
Conditions, however, are more favorable than in previous quarters due to a June price increase on the EPO brand, J&J says. With prices locked into 12-month contracts, it may take awhile for J&J to reap the full benefit of the price increase.
You may also be interested in...
J&J Expects Procrit Stability Under Medicare Average Sales Price Model
Despite volume gains, Procrit sales slumped 12% over the year due to pricing pressue. The growing EPO market coupled with pricing stability under Medicare Part B offers an opportunity for Procrit growth in 2005, Johnson & Johnson Worldwide Chairman Poon says.
J&J Expects Procrit Stability Under Medicare Average Sales Price Model
Despite volume gains, Procrit sales slumped 12% over the year due to pricing pressue. The growing EPO market coupled with pricing stability under Medicare Part B offers an opportunity for Procrit growth in 2005, Johnson & Johnson Worldwide Chairman Poon says.
Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says
The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.